

NJC

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.



www.rsc.org/njc



Conversion of lapachol to lomatiol: synthesis of novel naphthoquinone derivatives

Kenneth O. Eyong,^{a,b*} Kiran Chinthapally,^b Soundararasu Senthilkumar,^b Marc Lamshöft,^c Gabriel N. Folefoc,^a Sundarababu Baskaran^{b*}

Received 00th January 20xx,
Accepted 00th January 20xx

DOI: 10.1039/x0xx00000x

www.rsc.org/

Lapachol (**1**), a naphthoquinone isolated mostly from the plants of bignoniaceae family has a broad spectrum of biological activities and as a consequence it has been the object of different chemical transformations. Lomatiol (**3**), another naturally occurring naphthoquinone having structural similarities to lapachol, has been obtained from chemical and microbial transformations of lapachol with very low yields. In the present study, an easy approach for the synthesis of lomatiol (**3**) from lapachol (**1**) has been developed using SeO₂ oxidation in 90% yield. Lomatiol, under epoxidation conditions afforded novel furano- and pyrano-naphthoquinone derivatives, which are analogues of anticancer agents, 2-acetylfuronaphthoquinone and β-lapachone. Most of the structures were unambiguously confirmed by single crystal X-ray analysis.

Introduction

Lomatiol (**3**) a naturally occurring naphthoquinone isolated mainly from plants of the lomatia species particularly *L. denlab*, *L. ferrugiltea*, *L. oblique* has structural similarities to lapachol, a principal constituent of the Bignoniaceae family.^{1,2} Lapachol (**1**), exhibits a wide spectrum of biological activities including antibacterial, antiplasmodial, antioxidant, neurological and trypanocidal activities.³ Lapachol has also been used as anti-microbial and antiprotozoal agents and many of its derivatives are proved to be potent antimalarial and anti-HIV agents. β-Lapachone (Figure 1) is an antibacterial agent from lapachol while, atovaquone, a derivative of lapachol, has already been approved for the treatment of *Pneumocystis pneumonia*, toxoplasmosis and malaria.⁴




Figure 1. Some biologically active compounds derived from Lapachol.

Despite their structural similarities, there is no direct chemical conversion of lapachol to lomatiol. However, leucolapachol triacetate has been converted to lomatiol in several steps and with poor yield.⁵ Microbial transformation of lapachol has also been carried out using *cunninghamella echinulata*, *Beauveria sulfurescens*, *Streptomyces albus*, *Streptomyces griseus* to afford lomatiol and its derivatives with very low yields⁵ (Figure 2).

^aDepartment of Organic Chemistry, University of Yaounde 1, BP 812 Yaounde-Cameroon.

^bDepartment of Chemistry, Indian Institute of Technology Madras, Chennai-600 036, India.

^cBayer CropScience Aktiengesellschaft. Bcs AG-R & D-D-EnSa-MeA. Monheim, 6670, 273 Germany..

Electronic Supplementary Information (ESI) available: [details of any supplementary information available should be included here]. See DOI: 10.1039/x0xx00000x





Figure 2. Microbial transformation of lapachol to lomatol and its derivatives

Furano- and pyrano-naphthoquinone derivatives are known to exhibit significant biological activities. Among those compounds, 2-acetylfuranonaphthoquinone and β -lapachone show superior antitumoral activity and the influence of furan/pyran-ring in the antitumoral activity has recently been demonstrated.⁶ As a consequence of its biological significance, lapachol and its derivatives have become important synthetic targets. Recently, a mechanistic study on the Hooker oxidation of lapachol to afford norlapachol, in one of its most intriguing transformations have been carried out in our group.⁷ Our continued interest in converting lapachol (1) to various biologically active and pharmaceutically important molecules recently resulted in the neurological and the anti-tumor structure activity relationship studies of various naphthoquinones derived from lapachol.⁸


In the present study, we report SeO_2 oxidation of lapachol under different reaction conditions to afford the naturally occurring naphthoquinone, lomatol (3). Subsequent chemical transformation of lomatol afforded novel furano- and pyrano-naphthoquinone derivatives.


Results and discussion

In continuing our screening program of naphthoquinone derivatives of lapachol for bacterial, cancer and plasmodium activities, SeO_2 oxidation of lapachol (1), afforded the novel unsaturated aldehyde 2, which was subsequently reduced with NaBH_4 to give lomatol (3) in 30% yield. Nevertheless, lomatol was obtained in 50% yield upon reduction of compound 2 with $\text{NaBH}_4/\text{CeCl}_3$. Compound 2 on catalytic hydrogenation over Pd/C followed by acid hydrolysis afforded the acetal 4 and the corresponding aldehyde 5 (scheme 1). The structure of compound 2 was unambiguously confirmed by single crystal X-ray analysis (figure 3).^{9a}



Scheme 1. Synthesis of lomatol from lapachol.





Scheme 3. Sharpless asymmetric epoxidation of lomatiol

The stereochemistry of compounds **6** and **7** was assigned by single crystal X-ray structure determination (Figure 4).^{9b,9c}






Figure 4. ORTEP structure of compound (+)-6 and (+)-7


The *m*-CPBA epoxidation of lomatiol (**3**) afforded furano-naphthoquinone derivatives (±)-**6** (40%) and (±)-**7** (60%) as a mixture of diastereomers. The epoxidation reaction of lomatiol is regioselective since only the furano-naphthoquinone derivatives were formed in contrast to *m*-CPBA epoxidation of lapachol which resulted in the formation of both furano- and pyrano-naphthoquinone derivatives⁶ (scheme 4).

Scheme 4. *m*-CPBA treatment of lapachol


The *m*-CPBA epoxidation of acetate derivative of lomatiol **3b** afforded racemic epoxide (±)-**8** in 95% yield. Interestingly, under Sharpless asymmetric epoxidation conditions, compound **3b** furnished the corresponding optically active epoxide (+)-**8** in 80% yield with 90% ee (Scheme 5).

Scheme 5. *m*-CPBA and sharpless asymmetric epoxidation of **3b**

On the other hand, bromination of lomatiol derivative **3b** with bromine afforded pyrano-bromoethers **9a** & **9b** and furano-bromoethers **10a** & **10b**, respectively, as a mixture of diastereomers (scheme 6).

Scheme 6. Bromination of compound **3b**

Similarly, bromination⁶ of acetyl lapachol **1b** afforded the corresponding bromopyrano- derivative **11a** and bromofurano- derivative **11b**, respectively, in 92% and 5% yields. Treatment of bromopyrano- derivative **11a** with NaOH resulted in an unusual formylation reaction to give 3-bromo-3,4-dihydro-5-hydroxy-2,2-dimethyl-2H-benzo[h]chromene-6-carbaldehyde **13** along with the expected compounds **12** and **14** (Scheme 7).

Scheme 7. Unusual formylation reaction of compound **11a** with NaOH

The structure of compound **13** was unambiguously confirmed by single crystal X-ray analysis (figure 5).^{9d} while, the mechanism of formation is still under investigation.




Figure 5. ORTEP Structure of compound **13**

Conclusions

In conclusion, we have achieved the biomimetic synthesis of lomatiol (**3**) from lapachol (**1**) in 90% yield. The generality of this method was further shown on the methyl and acetyl derivatives of lapachol. Our efficient method for the synthesis of lomatiol (**3**) from lapachol (**1**) has provided an easy access to novel furano- and pyrano-naphthoquinone derivatives in good yields. The biological significance of newly synthesized lomatiol derivatives is being investigated.

Acknowledgements

Dr Eyong thanks the TWAS-UNESCO Associate Scheme and IIT Madras for financial Support. The authors thank the DST, UGC and CSIR, New Delhi, for financial support, and DST-FIST program for infrastructure facilities at IIT Madras. The authors also thank Mr V. Ramkumar for single crystal X-ray analysis. The Government of Cameroon for financial support through the 'Fonds d'Appuis à la Recherche'

Experimental

Synthesis of 4-(1,4-dihydro-2-hydroxy-1,4-dioxonaphthalen-3-yl)-2-methylbut-2-enal 2: To a stirred solution of lapachol **1** (200 mg, 0.8 mmol) in dioxane (12 mL) was added SeO₂ (249 mg, 2.24 mmol) and the resultant mixture was stirred at reflux temperature for 1 h. After completion of the reaction, as indicated by TLC, the reaction mass was filtered through silica gel and washed with EtOAc/hexane (1:1). The solvent was removed under reduced pressure to give crude product, which on column chromatographic purification over silica gel using 20–25% EtOAc in hexane as eluent afforded the pure aldehyde **2** (201 mg, 95% yield) as yellow crystals. IR (Neat) cm⁻¹: 3399, 3056, 2986, 2835, 2373, 2307, 1667, 1592, 1423, 1362, 1267, 1024, 896, 749; ¹H NMR (400 MHz, CDCl₃): δ 9.38 (s, 1H), 8.14 (d, J = 7.6 Hz, 1H), 8.11 (d, J = 7.6 Hz, 1H), 7.79 (td, J = 0.8, 7.6 Hz, 1H), 7.71 (td, J = 1.2, 7.6 Hz, 1H), 7.52 (s*, OH), 6.54 (td, J = 1.2, 7.6 Hz, 1H), 3.66 (d, J = 7.6 Hz, 2H), δ 1.91 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 195.2, 184.2, 181.3, 153.7, 149.1, 140.6, 135.4,

133.4, 132.9, 129.5, 127.1, 126.5, 120.2, 23.5, 9.4; HRMS (ESI) *m/z* calcd for C₁₅H₁₃O₄ (M⁺ + H) 257.2613, found 257.261.

Synthesis of (E)-2-hydroxy-3-(4-hydroxy-3-methylbut-2-enyl)naphthalene-1,4-dione 3: To a stirred solution of compound **2** (50 mg, 0.2 mmol) in MeOH (2 mL) was added CeCl₃·7H₂O (4 mg, 0.01 mmol) and NaBH₄ (8 mg, 0.22 mmol) and the resultant mixture was stirred at room temperature for 1 h. After completion of the reaction as indicated by TLC, the reaction mass was filtered and the solvents were removed under reduced pressure which was acidified with 1N HCl (4 mL) and extracted with DCM (2 × 5 mL). Combined organic layers were dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to give crude product, which on column chromatographic purification over silica gel using 30–40% EtOAc in hexanes as eluent afforded the pure lomatiol **3** (25 mg, 50% yield).

One-pot method for the synthesis of compound 3: To a suspension of SeO₂ (2.4 mg, 0.02 mmol) and salicylic acid (3.6 mg, 0.026 mmol) in dry DCM (2 mL) at 0 °C was added TBHP (163 μL, 6M) and the compound **1** (68 mg, 0.28 mmol) in dry DCM (2 mL) and the resulting solution was stirred at room temperature for 2 h. After completion of the reaction as indicated by TLC, water (5 mL) was added to the reaction mixture and extracted with DCM (2 × 5 mL). Combined organic layer was dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to give crude product, which on column chromatographic purification over silica gel using 30–40% EtOAc in hexane as eluent afforded the pure lomatiol **3** (65 mg, 90% yield) as a light yellow solid. IR (Neat) cm⁻¹: 3407, 3056, 2985, 2306, 1658, 1599, 1426, 1376, 1266, 1027, 897, 740; ¹H NMR (400 MHz, CDCl₃): δ 8.09 (d, J = 7.6 Hz, 1H), 8.05 (d, J = 7.2 Hz, 1H), 7.74 (t, J = 7.6 Hz, 1H), 7.67 (t, J = 7.6 Hz, 1H), 7.48 (s*, OH), 5.49 (t, J = 7.2 Hz, 1H), 3.99 (s, 2H), 3.48 (d, J = 7.2 Hz, 2H) and 1.86 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 184.6, 181.7, 153.1, 136.9, 135.1, 133.1, 132.9, 129.5, 126.9, 126.3, 122.9, 121.2, 68.7, 22.3, 13.9; HRMS (ESI) *m/z* calcd for C₁₅H₁₃O₄ (M⁺ + H) 259.0970, found 259.0963.

Synthesis of 2-hydroxy-3-(4,4-dimethoxy-3-methylbutyl)naphthalene-1,4-dione 4 and 4-(1,4-dihydro-2-hydroxy-1,4-dioxonaphthalen-3-yl)-2-methylbutanal 5: To a stirred solution of compound **2** (30 mg, 0.12 mmol) in MeOH (2 mL) was added Pd/C (6 mg) and stirred under 1 atm hydrogen atmosphere for 2 h. The reaction mixture was filtered through celite pad and the residue was washed with MeOH (2 × 5 mL). The filtrate was then concentrated under reduced pressure and the crude product was purified by column chromatography over silica gel (gradient elution with 12–15 % EtOAc in hexane) to give the corresponding acetal **4**. Acetal **4** was then treated with 2N HCl (2 mL) at 70 °C for 2 h. The reaction mixture was extracted with DCM (2 × 5 mL), the combined DCM layers were washed with water (5 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to give crude compound. Column chromatographic purification of the crude compound over silica gel (12–15% EtOAc in hexane) afforded the aldehyde derivative **5** (18 mg, 63% yield) as a yellow solid; **Compound 4** IR

(Neat) cm^{-1} : 3381, 2925, 2374, 1728, 1648, 1459, 1366, 1276, 1211, 1063, 938; ^1H NMR (400 MHz, CDCl_3): δ 8.10 (dd, $J = 0.8$, 7.6 Hz, 1H), 8.07 (dd, $J = 1.2$, 7.6 Hz, 1H), 7.74 (td, $J = 1.2$, 7.6 Hz, 1H), 7.67 (td, $J = 1.2$, 7.6 Hz, 1H), 7.39 (s*, OH), 4.09 (d, $J = 6.4$ Hz, 1H), 3.36 (s, 3H), 3.35 (s, 3H), 2.67–2.58 (m, 2H), 1.85–1.70 (m, 2H), 1.39–1.31 (m, 1H) and 1.01 (d, $J = 6.8$ Hz, 3H); ^{13}C (100 MHz, CDCl_3): δ 184.7, 181.5, 153.2, 134.9, 133.1, 133.0, 129.6, 126.9, 126.2, 124.8, 108.8, 54.4, 54.2, 36.1, 30.5, 21.0, 14.3; HRMS (ESI) m/z calcd for $\text{C}_{17}\text{H}_{20}\text{O}_5\text{Na}$ ($\text{M}^+ + \text{Na}$) 327.1208, found 327.1222. **Compound 5** was obtained as a yellow solid; IR (Neat) cm^{-1} : 3440, 3057, 2986, 2367, 2307, 1645, 1428, 1265, 894, 742; ^1H NMR (400 MHz, CDCl_3): δ 9.68 (d, $J = 1.6$ Hz, 1H), 8.12 (d, $J = 7.6$ Hz, 1H), 8.09 (d, $J = 7.6$ Hz, 1H), 7.77 (t, $J = 7.6$ Hz, 1H), 7.69 (t, $J = 7.6$ Hz, 1H), 7.38 (s*, OH), 2.69–2.64 (m, 2H), 2.44–2.39 (m, 1H), 2.04–1.95 (m, 1H), 1.18 (d, $J = 6.8$ Hz, 3H); HRMS (ESI) m/z calcd for $\text{C}_{15}\text{H}_{15}\text{O}_4$ ($\text{M}^+ + \text{H}$) 259.0970, found 259.0972.

(*R*)-2-((*S*)-1,2-dihydroxypropan-2-yl)-2,3-dihydronaphtho[2,3-*bj*]furan-4,9-dione (+)-**6** and (*R*)-2-((*S*)-1,2-dihydroxypropan-2-yl)-2,3-dihydronaphtho[1,2-*bj*]furan-4,5-dione (+)-**7**: To a stirred suspension of dried molecular sieves (60 mg) in dry CH_2Cl_2 (1 mL) was added L-(+)-diethyl tartrate (12 μL , 0.07 mmol) and titanium (IV) isopropoxide (17 μL , 0.06 mmol) at -23 $^\circ\text{C}$. After 10 min, TBHP (6M solution in decane, 581 μL , 0.348 mmol) was added. To this reaction mixture lomatiol **3** (30 mg, 0.116 mmol) dissolved in CH_2Cl_2 (1 mL) was added drop wise and the mixture was stirred for additional 7 h at -23 $^\circ\text{C}$ under nitrogen atmosphere. The reaction mass was allowed to reach 0 $^\circ\text{C}$, diluted with CH_2Cl_2 (4 mL) and layers were separated. Then CH_2Cl_2 layer was washed with saturated solution of Na_2SO_3 (3 \times 5 mL), brine solution (3 mL) and then dried over anhydrous Na_2SO_4 . The solvent was removed under reduced pressure to give the crude compound which was purified by column chromatography over deactivated silica gel (40–80% EtOAc in hexane) to afford pure compounds (+)-**6** (20% ee, 20% yield) and (+)-**7** (20% ee, 40% yield); **Compound (+)-6** was obtained as a yellow solid. $[\alpha]_D^{27} +18.2$ (c 0.1, CHCl_3); IR (Neat) cm^{-1} : 3395, 2922, 2850, 2376, 1635, 1463, 1388, 1246, 1199, 1049, 968; ^1H NMR (500 MHz, CDCl_3): δ 8.07 (d, $J = 7.5$ Hz, 2H), 7.72 (td, $J = 1.5$, 7.5 Hz, 1H), 7.68 (td, $J = 1.5$, 7.5 Hz, 1H), 5.05 (dd, $J = 9$, 11 Hz, 1H), 3.81 (d, $J = 11$ Hz, 1H), 3.58 (d, $J = 11$ Hz, 1H), 3.29 (dd, $J = 8.5$, 17.5 Hz, 1H), 3.20 (dd, $J = 11$, 17.5 Hz, 1H), 2.46 (s*, OH), 2.01 (s*, OH), 1.26 (s, 3H); ^{13}C NMR (125 MHz, CDCl_3): δ 182.3, 177.8, 159.9, 134.4, 133.2, 133.1, 131.6, 126.4, 126.2, 125.2, 87.5, 73.4, 66.8, 28.0, 19.0; HRMS (ESI) m/z calcd for $\text{C}_{15}\text{H}_{15}\text{O}_5$ ($\text{M}^+ + \text{H}$) 275.0919, found 275.0915. HPLC analysis of the compound **6** (Daicel AD-H, 20% IPA/hexane, flow rate 1 mL/min, $\lambda = 254$ nm, 20% ee): t_R 10.35 min (major enantiomer) and 12.85 min (minor enantiomer). **Compound (+)-7** was obtained as a red solid. $[\alpha]_D^{27} +54.5$ (c 0.24, CHCl_3); IR (Neat) cm^{-1} : 3448, 3056, 2986, 2924, 2853, 2685, 2306, 1647, 1426, 1266, 897, 739; ^1H NMR (500 MHz, CDCl_3): δ 8.04 (d, $J = 7.5$ Hz, 1H), 7.64–7.62 (m, 2H), 7.58–7.56 (m, 1H), 5.16 (dd, $J = 8.0$, 10 Hz, 1H), 3.80 (d, $J = 11$ Hz, 1H), 3.62 (d, $J = 11$ Hz, 1H), 3.20 (dd, $J = 7.5$, 15.5 Hz, 1H), 3.12 (dd, $J = 10$, 15.5 Hz, 1H), 1.27 (s, 3H); ^{13}C NMR (125 MHz, CDCl_3): δ 181.2, 175.5, 170.1, 134.7, 132.2, 130.7, 129.7, 127.4, 124.6, 116.2, 89.1, 73.5, 67.8, 27.1, 19.0; HRMS (ESI) m/z calcd

for $\text{C}_{15}\text{H}_{15}\text{O}_5$ ($\text{M}^+ + \text{H}$) 275.0919, found 275.0928. HPLC analysis of the compound **7** (Daicel AD-H, 20% IPA/hexane, flow rate 1 mL/min, $\lambda = 254$ nm, 20% ee): t_R 11.29 min (minor enantiomer) and 12.85 min (major enantiomer).

3-(((2*S*,3*S*)-3-(hydroxymethyl)-3-methyloxiran-2-yl)methyl)-1,4-dioxo-1,4-dihydronaphthalen-2-yl acetate (+)-**8**: Sharpless asymmetric epoxidation of the compound **3b** (60 mg, 0.2 mmol) following the above procedure afforded (+)-**8** (50 mg, 80%) as light yellow oil; $[\alpha]_D^{27} +101.1$ (c 0.2, CHCl_3); IR (Neat) cm^{-1} : 3396, 3298, 2921, 2372, 1745, 1616, 1391, 1225, 1066; ^1H NMR (400 MHz, CDCl_3): δ 8.13–8.08 (m, 2H), 7.77–7.72 (m, 2H), 3.65 (d, $J = 12$ Hz, 1H), 3.55 (d, $J = 12.4$ Hz, 1H), 3.23 (t, $J = 6$ Hz, 1H), 2.94 (dd, $J = 5.2$, 13.6 Hz, 1H), 2.80 (dd, $J = 6.8$, 13.6 Hz, 1H), 2.40 (s, 3H), 1.40 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3): δ 184.3, 177.9, 168.0, 152.5, 135.5, 134.4, 134.1, 131.9, 126.9, 126.8, 65.1, 61.7, 58.0, 23.8, 20.6, 14.4; HRMS (ESI) m/z calcd for $\text{C}_{17}\text{H}_{17}\text{O}_6$ ($\text{M}^+ + \text{H}$) 317.1025, found 317.1032. HPLC analysis of the compound (+)-**8** (Daicel AD-H, 20% IPA/hexane, flow rate 1 mL/min, $\lambda = 254$ nm, 90% ee): t_R 17.54 min (major enantiomer) and 19.82 min (minor enantiomer).

Bromination of compound 3b: To a stirred solution of compound **3b** (30 mg, 0.1 mmol) in dry DCM (2 mL) at 0 $^\circ\text{C}$ was added bromine (6 μL , 2.4 mmol). The resultant reaction mixture was stirred for 15 min at room temperature. The reaction mixture was quenched with saturated solution of $\text{Na}_2\text{S}_2\text{O}_3$ and extracted with DCM (2 \times 5 mL), the combined DCM layers were washed with water (5 mL), dried over anhydrous Na_2SO_4 and concentrated under reduced pressure to give crude compound. Column chromatographic purification of the crude compound over silica gel (40–70% EtOAc in hexane) afforded the bromo derivatives **9a**, **9b**, **10a** and **10b**. **Compound 9a** and **9b**: IR (Neat) cm^{-1} : 3058, 2985, 2874, 1741, 1656, 1445, 1375, 1268, 1239, 1097, 1047, 938, 847, 744, 705; ^1H NMR (400 MHz, CDCl_3): δ 8.19 (dd, $J = 0.8$, 8.0 Hz, 2H), 7.91 (td, $J = 0.8$, 8.0 Hz, 2H), 7.79 (qd, $J = 1.2$, 7.6 Hz, 2H), 7.63 (qd, $J = 1.2$, 8.0 Hz, 2H), 4.46 (d, $J = 8.4$ Hz, 1H), 4.36 (dd, $J = 1.2$, 5.6 Hz, 1H), 4.25 (dd, $J = 1.2$, 6.0 Hz, 1H), 4.20 (d, $J = 8.4$ Hz, 1H), 4.09 (d, $J = 8.4$ Hz, 1H), 3.93 (d, $J = 8.4$ Hz, 1H), 3.67 (dd, $J = 1.2$, 15.6 Hz, 1H), 3.46 (dd, $J = 5.6$, 18.0 Hz, 1H), 3.24 (dd, $J = 6.0$, 15.6 Hz, 1H), 2.91 (dd, $J = 1.2$, 17.6 Hz, 1H), 1.81 (s, 3H), 1.54 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3): δ 182.3, 180.8, 180.2, 179.1, 138.0, 137.8, 135.7, 131.3, 131.2, 131.1, 130.9, 129.1, 128.8, 125.9, 125.3, 106.8, 84.2, 83.9, 77.5, 75.5, 74.2, 62.9, 58.6, 50.5, 47.9, 37.2, 34.9, 22.7, 22.6; HRMS (ESI) m/z calcd for $\text{C}_{15}\text{H}_{14}\text{O}_4\text{Br}$ ($\text{M}^+ + \text{H}$) 337.0075, found 337.0075. **Compound 10a**: IR (Neat) cm^{-1} : 3410, 3357, 3284, 2920, 2369, 1643, 1402, 1078, 819, 629; ^1H NMR (400 MHz, CDCl_3): δ 8.10 (d, $J = 7.2$ Hz, 1H), 7.69–7.58 (m, 3H), 5.26 (t, $J = 8.8$ Hz, 1H), 4.44 (s, 2H), 3.30–3.27 (m, 2H), 2.16 (s, 3H), 1.25 (s, 3H); HRMS (ESI) m/z calcd for $\text{C}_{15}\text{H}_{14}\text{O}_4\text{Br}$ ($\text{M}^+ + \text{H}$) 337.0075, found 337.0092.

Synthesis of 3-bromo-3,4-dihydro-5-hydroxy-2,2-dimethyl-2H-benzo[h]chromene-6-carbaldehyde 13: To a stirred solution of compound **1b** (184 mg, 0.65 mmol) in DCM (4 mL) was added bromine (53 μL , 1.04 mmol) and the resultant reaction mixture was stirred at the room temperature 2 h. After completion of

the reaction as indicated by TLC, the solvent was removed under reduced pressure to give crude product, which on column chromatographic purification over silica gel using 40-45% EtOAc in hexane as eluent afforded the pure compounds **11a** (93% yield) and **11b**⁶ (5% yield). Compound **11a** (75 mg, 0.23 mmol) was treated with 3N NaOH at rt for 2 h. After completion of the reaction as indicated by TLC, reaction mixture was diluted with DCM and extracted using DCM (2 x 5 mL) and water (5 mL). The combined DCM layers were washed with brine solution and dried over Na₂SO₄ and solvent was removed under reduced pressure to give crude product, which on chromatographic purification over silica gel using 15% EtOAc in hexane as eluent afforded the pure compounds **12** (65% yield), **13** (15% yield) and **14** (5% yield). Compound **13** was obtained as white crystals. ¹H (500 MHz, CDCl₃) δ 14.04 (s, 1H), 10.49 (s, OH), 8.17 (d, *J* = 8.4 Hz, 1H), 8.11 (d, *J* = 8.4 Hz, 1H), 7.60 (t, *J* = 7.2 Hz, 1H), 7.42 (t, *J* = 7.6 Hz, 1H), 4.36 (dd, *J* = 5.5, 8.0 Hz, 1H), 3.50 (dd, *J* = 8.0, 17.6 Hz, 1H), 3.26 (dd, *J* = 8.0, 17.6 Hz, 1H), 1.65 (s, 1H), 1.56 (s, 1H); ¹³C (125 MHz, CDCl₃): δ 190.8, 165.7, 156.4, 132.7, 129.6, 123.9, 122.9, 120.4, 118.3, 106.2, 105.2, 79.1, 50.93, 28.4, 26.6, 22.8; HRMS (ESI) *m/z* calcd for C₁₆H₁₆BrO₃ (M⁺ + H) 335.0283, found 335.0280.

Notes and references

1. Hooker, S. *J.A.C.S.* 1936, **58**, 1181-1191
2. (a) Eyong, K. O.; Krohn, K.; Hussain, H.; Folefoc, G. N.; Nkengfack, A. E.; Schulz, B.; Hu, Q. *Chem. Pharm. Bull.* 2005, **53**, 616-619; (b) Eyong, K. O.; Folefoc, G. N.; Kuete, V.; Beng, V. P.; Krohn, K.; Hussain, H.; Nkengfack, A. E.; Saefel, M.; Sarite, S. R.; Hoerauf, A. *Phytochemistry* 2006, **67**, 605-609.
3. (a) Kuete, V.; Eyong, K. O.; Folefoc, G. N.; Beng, V. P.; Hussain, H.; Krohn, K.; Nkengfack, A. E. *Pharmazie* 2007, **62**, 552-556; (b) Wenceslau, J. P. S.; De Souza, D. F.; De Oliveira, M. C. F.; Lemos, T. L. G.; De Sousa, A. L.; Trevisan, M. T. S.; De Mattos, M. C. *Nat. Prod. Commun.* 2006, **1**, 661; (c) Schmeda-Hirschmann, G.; Papastergiou, F. *Z Naturforsch* 2003, **58**, 495-501; (d) Duarte, D. S.; Dolabela, M. F.; Salas, C. E.; Raslan, D. S.; Oliveiras, A. B.; Nenninger, A.; Wiedemann, B.; Wagner, H.; Lombardi, J.; Lopes, M. T. P. *J. Pharm. Pharmacol.* 2000, **52**, 347-352; (e) Gormann, R.; Kaloga, M.; Li, X.-C.; Ferreira, D.; Bergenthal, D.; Kolodziej, H. *Phytochemistry* 2003, **64**, 583-587.
4. Baramee, A.; Coppin, A.; Mortuaire, M.; Pelinski, L.; Tomavo, S. *Bioorg. Med. Chem.* 2006, **14**, 1294-1302.
5. (a) Gates, M. *J.A.C.S.* 1948, **70**, 617-18 (b) Otten, S. L.; Rosazza, J. P. *J. Nat. Prod.* 1981, **44**, 561-568 (c) Lucien, D.; Gayet, J. C.; Veschambre, H. *Agric. Biol. Chem.*, 1985, **49**, 2693-2698.
6. (a) Perez-Sacau, E.; Diaz-Penate, R. G.; Estevez-Braun, A.; Ravelo, A. G.; Garcia-Castellano, J. M.; Pardo, L.; Campillo, M. *J. Med. Chem.* 2007, **50**, 696-706; (b) Sergio, R.; Peraza, S.; Daniel, C.; Hee-Byung, C.; Young, G. S.; Ricardo, G.; Miliciades, M.; Craig, R. F.; Kate, E. L.; Ana, T. M.; Norman, R. F.; Geoffrey, A. C.; John, M. P.; Douglas, A. K. *J. Nat. Prod.* 2000, **63**, 492.
7. Eyong, K. O.; Puppala, M.; Kumar, P. S.; Lamshöft, M.; Folefoc, G.N.; Spitteller, M.; Baskaran, S. *Org. Biomol. Chem.* 2013, **11**, 459-468.
8. (a) Eyong, K. O.; Kumar, P. S.; Kuete, V.; Folefoc, G. N.; Nkengfack, A. E.; and Baskaran, S. *Bioorg. Med. Chem. Lett.*, 2008, **18**, 5387-5390; (b) Eyong, K. O.; Kumar, P. S.; Kuete, V.; Folefoc, G. N.; Langmi, H.; Meyer, M. J. J.; Lall, N.; and Baskaran, S. *Med. Chem. Res.*, 2012, **21**, 2117-2122. (c) Eyong, K. O.; Foyet, H. S.; Eyong, C. A.; Sidjui, L. S.; Yimdjo, M. C.; Nwembe, S. N.; Lamshoft, M.; Folefoc, G. N.; Spitteller, M.; Nastasa, V. *Med. Chem. Res.* 2013, **22**, 2902-2911.
9. (a) CCDC 971195, (b) CCDC 971197 (c) CCDC 971196 (d) CCDC 971194 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge from the Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif.
10. Tanis, S. P. *J. Org. Chem.* 1988, **53**, 4929-4938
11. Katsuki, T.; Sharpless, K.B., *J. Am. Chem. Soc.*, 1980, **102**, 5974-5976.

Supplementary Material

NMR Spectral data of novel derivatives can be found in Supplementary material.

GRAPHICAL ABSTRACT

Conversion of lapachol to lomatiol: synthesis of novel naphthoquinone derivatives

Kenneth O. Eyong,^{a,b*} Kiran Chinthapally,^b Soundararasu Senthilkumar,^b Marc Lamshöft,^c Gabriel N. Folefoc,^a Sundarababu Baskaran^{b*}

Biomimetic synthesis of lomatiol from lapachol and subsequent transformation of lomatiol to biologically important furano- and pyrano-naphthoquinone derivatives have been reported.

